MRNA Story - On A Smaller ScaleIn continuation of the previous idea, I wanted to cover the shorter time frame move on $NASDAQ:MRNA.
Really, this is a more simple analysis as the base is clearly set on the weekly chart. I should note I have analyzed the consolidation on the 2-Week time period. The 2-Week time period does also give a range expansion signal, but for a more detailed look I am showing the 1-Week time period.
With the current base, and a measure of this consolidation range (from low to high), a first target of $42.76 can be obtained. If the trend continues in a really strong fashion, a second target of $68.17 would look to be hit. Sometimes when an explosive move like this happens, a retest of the mode can occur like in the example path shown below. However, just as the continuation of this trend remains to be seen, so does any retest of this move. Make bets accordingly.
Whether the trend continues, and how strong it remains, of course is yet to be determined. But this analysis allows for educated guesses to be made and positions to be taken.
Best of luck to all of us who are entering positions and looking for continuation of this trend reversal play.
Pasting the regular weekly chart (no path) here:
Enjoy,
Reagen
MRNA
Moderna - Upside PotentialSince August 2021, Moderna’s stock has been in a downtrend.
The latest decline started in May 2024 and ended in April 2025, dropping from 170 to 23 .
Since April 2025, a corrective move has begun for one of the sub-waves.
This move is nearly complete, with final targets at 36 -> 38 .
This does not mean the uptrend is over - after some time and additional corrections, we should see a move toward 57 .
The longer-term outlook remains clear and largely positive.
For now, let's focus on the targets mentioned. Further developments will be shared in new ideas.
---
Please subscribe and leave a comment.
You’ll get new information faster than anyone else.
---
$MRNA I might full port..Everything is noted in the chart for visualization. We have local resistance around $27 which I don't think is an issue. This name is at 5 year lows with an incredible 67% haircut over the span of a year and change, if that. NASDAQ:MRNA just crushed its last earnings beat and it dropped. A controlled and manipulated drop in my opinion. Healthcare names may have a beautiful end of the year. This is a great name to acquire for mid to long term portfolios just in shares itself. I personally will be entering calls for dated out. I am currently in $30 calls for 10/17 expiration. I expect this name to make a full 100% recovery into the psyche level of $50 in the months to come.
$MRNA – Long-Term Setup Brewing | Major Move Incoming?Moderna ( NASDAQ:MRNA ) may be gearing up for a multi-month reversal after a prolonged downtrend. Price action is compressing in a tight base, suggesting a potential 6+ month breakout could be in the cards.
📊 Key Technical Notes:
Trading near long-term support with signs of accumulation
Bullish divergence forming on RSI and MACD
Volume contraction hints at a volatility expansion ahead
Overhead resistance sits between $60–$80, aligning with previous breakdown levels from 2023
⚠️ Breakout Trigger: Watch for a decisive move above $29.50–$30 on volume. A sustained breakout could initiate a powerful move toward the $60–$80 resistance zone.
📍 Levels to Watch:
Breakout zone: $29.50–$30
Resistance targets: $60, then $80
Key support: $25–$26
🧠 This is a longer-term swing trade idea — ideal for patient traders looking to front-run institutional rotation into beaten-down biotech names.
#MRNA #Moderna #SwingTrade #BiotechStocks #LongTermSetup #TechnicalAnalysis #StockMarket #BreakoutSetup #OptionsTrading #TradingView
Is Gene Editing's Investment Promise Within Reach?CRISPR Therapeutics stands at the vanguard of the gene editing revolution, transitioning into a commercial-stage biopharmaceutical entity following the landmark approval of CASGEVY. This first-of-its-kind gene editing treatment targets sickle cell disease and beta-thalassemia, validating the transformative potential of CRISPR-Cas9 technology and signaling the dawn of a new medical era. CASGEVY's market entry provides critical proof of concept, paving the way for broader gene editing applications in treating genetic disorders.
Despite this scientific triumph, CASGEVY's commercial launch faces immediate hurdles, primarily its high cost and complex administration, contributing to slow initial sales. While development partner Vertex Pharmaceuticals reports the revenue, CRISPR receives a profit share. The company currently operates at a loss, with operating expenses significantly exceeding revenue, primarily from grants. However, a robust cash reserve provides financial stability as CRISPR pursues an ambitious pipeline targeting widespread diseases like cancer, diabetes, and cardiovascular conditions, alongside its commercial efforts with CASGEVY.
The intellectual property landscape remains dynamic, marked by ongoing patent disputes over the foundational CRISPR-Cas9 technology, which could influence future licensing and competition. Simultaneously, CRISPR Therapeutics contributes to advancements in personalized medicine and delivery systems. A notable achievement includes the rapid development and delivery of a personalized mRNA-based CRISPR therapy for a rare metabolic disorder using lipid nanoparticles, demonstrating a potential model for swift, patient-specific treatments and highlighting the crucial role of advanced delivery technologies in expanding gene editing's therapeutic reach.
For investors, CRISPR Therapeutics presents a high-risk, high-reward opportunity. The stock has experienced volatility, reflecting current unprofitability and market conditions. Yet, strong institutional ownership and optimistic analyst ratings underscore confidence in the long-term potential. The company's deep pipeline and foundational technology position it for significant future growth if clinical programs succeed and commercial adoption of its therapies expands, suggesting that for those with a long-term perspective, the promise of gene editing may indeed be within reach.
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MRNA Shares Drop?
On Monday, MRNA led the decline among US biotech stocks following the resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks had held this position for over a decade.
During Trump’s first term, Marks oversaw the rollout of COVID-19 vaccines and established guidelines for emerging treatments such as cell and gene therapy.
However, in Trump’s second term, Robert F. Kennedy Jr. now serves as Health Secretary. According to The Wall Street Journal, Marks criticised Kennedy’s stance on vaccines in his resignation letter, calling it “misinformation and lies.”
The pharmaceutical industry was already under pressure amid speculation that Trump’s tariff plans could extend to prescription drugs, which are typically exempt from such measures. Marks' departure has further intensified uncertainty regarding regulatory decisions under the new administration.
Technical Analysis of MRNA Shares
The chart indicates that:
➝ The stock remains in a downtrend that began with a sharp drop in August last year (reinforced by the moving average).
➝ Over the past five months, it has been forming a descending channel (marked in red).
➝ The lower boundary of this channel acted as support yesterday.
The formation of higher lows and highs (marked in blue) had given bulls some hope in March 2025. However, yesterday’s bearish gap appears to have shattered that optimism.
It is possible that the lower blue trendline and the median of the red channel will act as resistance moving forward, further darkening the outlook for MRNA’s share price—especially given the ongoing negative news surrounding the stock.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
$MRNA: Moderna – mRNA Magic or Biotech Bubble?(1/9)
Good afternoon, folks! ☀️ NASDAQ:MRNA : Moderna – mRNA Magic or Biotech Bubble?
CEO drops $5M on shares, sparking a 9% surge—is this a biotech rocket or a hot air balloon ready to pop? Let’s crack the code! 🔍
(2/9) – PRICE PERFORMANCE 📊
• Current Trend: Up 9% after CEO’s $5M buy on Mar 5, 2025 💰
• Context: Biotech’s a rollercoaster—posts on X show optimism 📈
• Sector Vibe: Volatile, but insider faith lifts spirits 🌈
It’s a wild climb—buckle up! ⚡
(3/9) – MARKET POSITION 📈
• Market Cap: Around $12B (based on 384M shares, est.) 🏅
• Operations: mRNA pioneer, vaccines to cancer therapies ⏳
• Trend: CEO’s move signals undervaluation hope 🎯
Solid player in the biotech jungle! 🌋
(4/9) – KEY DEVELOPMENTS 🔑
• Insider Buying: CEO’s $5M grab on Mar 5, 2025 🔄
• Buzz: Posts on X tie surge to leadership confidence 🌐
• Reaction: Market cheers, up 9% in a blink 📣
Risin’ like dough in a warm oven! 🔥
(5/9) – RISKS IN FOCUS ⚠️
• Volatility: Biotech swings wild amid macro uncertainty 🔎
• Policy: Healthcare shifts could sting 📉
• Pipeline: New products unproven, per X chatter 🌬️
High stakes, high drama! 🎭
(6/9) – SWOT: STRENGTHS 💪
• Innovation: mRNA tech reshapes medicine 🏆
• Confidence: CEO’s $5M bet screams belief 📊
• Legacy: COVID vaccine king, still swinging ⚒️
A biotech beast with bite! 🐺
(7/9) – SWOT: WEAKNESSES & OPPORTUNITIES ⚖️
• Weaknesses: Volatility, macro jitters hit hard 📉
• Opportunities: New mRNA goodies, partnerships loom 📈
Can it brew more magic or fizzle out? 🧪
(8/9) – 📢 Stock up 9% after CEO’s $5M buy—your call? 🗳️
#
• Bullish: $50+ soon, biotech boom 🚀
• Neutral: Holding steady, risks weigh ⚖️
• Bearish: $25 looms, bubble bursts 🐻#
Drop your vote below! 👇
(9/9) – FINAL TAKEAWAY 🎯
Moderna’s 9% pop on insider buying hints at hidden gems 📈, but biotech’s a stormy sea 🌊. Dips are our playground—DCA heaven 💸. Snag ‘em cheap, ride the wave! Winner or wild card?
Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment among investors.
Weighing the Challenges and Opportunities
On Friday, Moderna disclosed a Q4 2024 revenue of $966 million, marking a sharp 65% year-over-year decline. The loss per share stood at $2.91, exceeding the analyst projection of $2.73 per share. More concerning for investors was the company’s forecast for 2025 sales, estimated between $1.5 billion and $2.5 billion—significantly below the $3.26 billion consensus estimate.
CEO Stéphane Bancel reaffirmed Moderna’s focus on cutting costs and streamlining its research and development (R&D) efforts. The company plans to reduce R&D expenses by up to $1.1 billion by 2027, primarily by halting early-stage projects and prioritizing late-stage drug approvals. Moderna has already trimmed $1 billion in costs, positioning itself for leaner operations in the coming years.
Technical Analysis: Key Levels to Watch
From a technical perspective, NASDAQ:MRNA shares closed Friday’s session down 0.38%, showing hesitation despite the broader market’s strength. The stock is currently hovering near a critical support zone—the one-month low. Should this level fail to hold, a further decline towards the $25 region could be the next stop.
On the upside, a breakout above the 38.2% Fibonacci retracement level could alter the trajectory for Moderna’s stock, potentially signaling a bullish reversal. However, with the Relative Strength Index (RSI) at 41.46, the stock remains in weak momentum territory, suggesting that bullish conviction is still lacking.
Outlook: Can Moderna Reignite Investor Confidence?
Moderna’s near-term outlook remains uncertain, as the company grapples with declining COVID vaccine sales, weaker-than-expected 2025 revenue projections, and an ongoing shift in its R&D strategy. However, its pipeline of combination vaccines and upcoming approvals may offer a longer-term upside if execution is successful.
Technically, NASDAQ:MRNA needs to hold its key support zone and break above the 38.2% Fibonacci retracement to shift market sentiment positively. Until then, investors should watch for further signals of strength, particularly in trading volume and RSI movement, before confirming a potential bullish turnaround.
In the coming months, all eyes will be on Moderna’s next earnings report and the market’s reaction to its cost-cutting measures and pipeline advancements. The stock’s ability to sustain recent gains—or break lower—will depend on whether the company can deliver on its strategic shifts and stabilize its revenue trajectory.
MRNA Moderna Options Ahead of EarningsIf you haven`t bought MRNA before the previous earnings:
Now analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 45usd strike price Calls with
an expiration date of 2025-9-19,
for a premium of approximately $3.65.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
$MRNA to $90-115 | 100-150% upside in FY 2025- NASDAQ:MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco.
- This company is beaten down to the ground and has low market cap as compared to other biopharma stocks.
- 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth.
- Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
$MRNA has 50-100% upside from $43 in FY 2025- NASDAQ:MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research.
- NASDAQ:MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term.
- In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year.
- Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.
The Share Price of Moderna (MRNA) Surged Over 10% in a DayThe Share Price of Moderna (MRNA) Surged Over 10% in a Day
As shown by the chart of pharmaceutical company Moderna (MRNA):
→ 2024 was an extremely difficult year, with the price falling by approximately 60%;
→ however, in early 2025, we can see signs of renewed strength.
During yesterday’s session, Moderna’s (MRNA) share price rose by more than 10%, following news of the first death in the US from H5N1 bird flu. According to Barron’s, Moderna is one of the few pharmaceutical companies currently developing a vaccine for H5N1 bird flu, which is spreading rapidly across North America.
This brings back memories of 2020, when MRNA’s share price surged with a significant bullish gap on news of the COVID-19 vaccine trials.
Interestingly, the 2024 low is near the lower boundary of the 2020 gap, around the $37 level. From a technical analysis perspective, this “gap closure” could be viewed as a bullish sign, supported by yesterday’s price action.
Additionally:
→ there has been a breakout above the descending trend channel that dominated the end of 2024;
→ it is possible that price movements may form a new ascending channel (shown in blue);
→ further growth may be hindered by the psychological resistance level of $50.
According to TipRanks, analysts remain cautious about Moderna’s prospects:
→ only 4 out of 19 analysts recommend buying MRNA shares;
→ the average 12-month price target for MRNA is $62.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Halftime Update: MRNA - Moderna AnalysisMRNA is currently retesting a pivotal level of resistance that we believe could provide a greater push back to those higher $58.55 Price Levels as long as it can keep this momentum that it has, seeing a very large volume spike in this morning. If not, we would expect some consolidation back to $45.42 levels before pushing higher.
Stock jumped this morning after reporting a potential vaccine to combat the recent H5N1 Bird Flu. This comes after the first human death due to the Bird Flu in Louisiana, although the patient did have pre-existing medical conditions that contributed to the death, not to stir any feathers.
Don't really have a price projection or entry specifically for this as we're watching. This could pull back to those EMAs before gaining True Momentum Northward.
Connect with us by visiting the website below in our signature to get even more at @MyMIWallet
#MyMIWallet
Moderna (MRNA): mRNA Leader Trading at a 90% Discount1️⃣ mRNA Technology Leadership: Moderna is revolutionizing vaccine development with its cutting-edge mRNA platform, positioning itself as a leader in the future of healthcare innovation.
2️⃣ Analyst Targets: With 28 ratings averaging $71.40 and highs of $85, Moderna offers over 60% upside from current levels.
3️⃣ Expanding Pipeline: Moderna’s broadening pipeline includes a variety of treatments, giving it multiple high-growth opportunities in the healthcare sector.
4️⃣ Technical Momentum: Moderna is holding key support at $43.85, with bullish signals of upward movement. The stock is primed for a breakout, supported by increasing volume and positive market sentiment.
📈 Trade Setup:
🎯 Take Profit 1: $50 (+14% potential gain)
🎯 Take Profit 2: $60 (+37% potential gain)
🏆 Take Profit 3: $70 (+59% potential gain)
📉 Stop Loss: $35 ⚠️ (For those with a conservative risk profile, but not necessary for long-term holders like myself)
MRNA Moderna Among My Top 10 Picks for 2025 | Price TargetIf you haven`t bought MRNA on the recent breakout:
My price target for MRNA in 2025 is $55, driven by the following fundamental factors:
Innovative mRNA Technology and Expanding Pipeline:
Moderna has established itself as a leader in mRNA technology, initially gaining prominence through its COVID-19 vaccine. The company is now leveraging this innovative platform to develop a diverse array of therapeutic candidates, with approximately 40 development projects in progress across various fields, including infectious diseases, oncology, and rare genetic disorders. This broad pipeline not only enhances Moderna's potential for future revenue but also positions it to capitalize on emerging healthcare needs as the demand for advanced therapies continues to rise.
Projected Revenue Growth:
Despite facing financial challenges, including recent losses, Moderna's revenue outlook remains promising. The company is forecasting sales between $2.5 billion and $3.5 billion for 2025, which analysts believe could be conservative given the anticipated rollout of new vaccines and treatments. If successful, these products could significantly boost sales and profitability, driving investor confidence and stock price appreciation 16. Market projections suggest that if Moderna successfully navigates its clinical trials and product launches, the stock could reach around $80 per share by 2025.
Strategic Partnerships and Collaborations:
Moderna's strategic collaborations with major pharmaceutical companies enhance its development capabilities and market access. These partnerships are crucial for accelerating product development and increasing the adoption of its mRNA technology across various therapeutic areas. By aligning with established players in the industry, Moderna can leverage additional resources and expertise to bring its innovations to market more effectively.
Market Sentiment and Recovery Potential:
Currently trading at lower valuations due to past performance fluctuations, Moderna's stock is positioned for recovery as investor sentiment shifts with positive developments in its pipeline. The company's five-year growth trajectory shows resilience despite recent setbacks, indicating potential for a rebound as new products come to market. Analysts remain optimistic about Moderna's long-term prospects, suggesting that as the market recognizes the value of its innovative therapies, the stock could see substantial gains.
$MRNA can’t find a bottomThis name has been on my watch the last 6 months. I continued to wait for a possible bottom for a position but every time it pops it just goes down some more. Another delisting here on the $NASDAQ. I expect this to reach newer lows below $36. NASDAQ:SMCI in the same boat. This chart actually looks prime for more downside with these candles. Short it.
WALLSTREETLOSER
$MRNA hasn't been here since APRIL 2020.. pt. 2Posted a quick chart via phone earlier but had to take a look on the desktop. A crucial point here at a supply that once took off 4 years ago.. interesting. Target is $35, leave runners once $36 hits. This could have been a bottom for NASDAQ:MRNA but after the rebalancing of the NASDAQ this may bottom out at $30.
WSL
Potential massive reversal for MRNA?🔉Sound on!🔉
Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
Moderna (MRNA) Stock Plummets on Weak Sales OutlookModerna Inc. (NASDAQ: NASDAQ:MRNA ) is facing tough times as its stock dropped over 11% during Thursday’s premarket trading session. The biotech giant, known for its breakthrough COVID-19 vaccine, released a disappointing sales outlook for the upcoming years, sparking a significant sell-off among investors.
Weak Sales Outlook and Pipeline Adjustments
Moderna (NASDAQ: NASDAQ:MRNA ) has projected sales between $2.5 billion and $3.5 billion for 2025, a far cry from the multi-billion dollar revenues seen during the peak of the COVID-19 pandemic. This forecast falls below analysts’ expectations, who anticipated revenues of $3.27 billion for 2024 and $3.74 billion for 2025.
The company’s revenue has been declining since the pandemic boom, with 2023 expected to be the lowest annual revenue since its first COVID-19 vaccine launch in late 2020. Moderna (NASDAQ: NASDAQ:MRNA ) is now betting on its 10 new product launches by 2027 to drive an average annual growth rate of 25% in revenue between 2026 and 2028. However, Moderna CFO James Mock highlighted the uncertainty of the COVID-19 and RSV markets, admitting that these new products may not contribute significant revenue until later years.
Moderna’s strategic pivot includes significant cost-cutting measures, with plans to slash $1.1 billion in expenses by 2027. This includes reducing R&D spending from an expected $4.8 billion this year to between $3.6 billion and $3.8 billion by 2027. Despite these reductions, the company is still committed to advancing its pipeline, which includes new mRNA vaccines against RSV, norovirus, and cancer, among others.
Challenges Ahead: Competition and Pipeline Delays
Moderna’s market position is increasingly challenged by competitors like Pfizer (PFE) and GSK (GSK), who are also pursuing expanded approvals for their RSV vaccines in the same high-risk adult age groups. Moderna’s recent decision to drop its request for fast-track approval of its standalone flu vaccine reflects its strategic realignment towards combination shots that offer protection against multiple viruses, including COVID-19 and influenza.
The company's standalone flu shot, mRNA-1010, recently met immune-response targets in clinical trials, but it's still a long way from regulatory approval. Moderna's CEO, Stéphane Bancel, remains optimistic about the company's robust drug development capabilities, boasting that Moderna's rate of success from phase one to phase three trials is “six times higher” than the industry average.
Technical Outlook
Technically, Moderna's stock price is reflecting the weak fundamentals. The stock is down 10.45% in premarket trading, which adds to the already bearish momentum. On Wednesday, the Relative Strength Index (RSI) for Moderna (NASDAQ: NASDAQ:MRNA ) was 37, indicating a weakened position. The current dip below the $73 mark will likely push the RSI further into oversold territory, raising concerns about heightened selling pressure.
The critical technical level to watch is the $60 pivot, a major support zone that aligns with the September 2020 lows. Should Moderna’s stock breach this support, it could trigger a cascade of selling as investors lose confidence, potentially leading to a more severe downturn. This level has historically served as a strong base, and a breakdown could erase gains made over the last four years.
What’s Next for Moderna?
While Moderna’s long-term prospects hinge on the successful launch of its new mRNA-based therapies, the immediate outlook appears bleak. The company’s efforts to expand into new markets like RSV and flu vaccines are promising, but the revenue impact of these products won’t be felt until at least 2025. Investors should brace for volatility as the company navigates through a post-pandemic market landscape with reduced COVID-19 vaccine sales and increasing competition.
For now, Moderna's technical indicators signal caution. The stock's proximity to major support zones and the bearish momentum could prompt further declines if market sentiment does not improve. Investors are advised to keep a close eye on how the company’s strategic decisions unfold and whether Moderna (NASDAQ: NASDAQ:MRNA ) can successfully deliver on its ambitious pipeline goals in the face of growing market challenges.
MRNA, bound for exponential growth! MASSIVE RISE in 12 months!MRNA went parabolic during the COVID era reaching as high as 500. Then it went on a cooling down mode coincindingly when the pandemic has started fading.
Now a BIG SHIFT has been registered based on its long term data metrics. This is massive because it took the stock 2.5 years to make this happen again.
A breakout has been spotted on its long term trend. We got a break in structure confirming that major position takers has started piling up already for that new round of massive growth prospect.
Histogram registered it's elusive 'hop' over the line already. First time in ages. The most awaited confirmation is ON.
Best seeding season is NOW.
This will be an investors' gem.
Spotted at 140.0
Interim target at 300.0
Long term: 500.
TAYOR.






















